Kappa Bioscience granted new patent of intermediaries used in synthesizing vitamin K2 MK-7

April 16, 2020

Kappa Bioscience has been granted U.S. Patent No. 10,472,314, titled “Process for the Preparation of Vitamin K2.” 

Kappa Bioscience has been granted U.S. Patent No. 10,472,314, titled “Process for the Preparation of Vitamin K2.” This patent applies to the critical intermediaries used in the synthesis of its vitamin K2 MK-7.

“We were delighted with the patent award as recognition of Kappa’s investment into innovation in MK-7 synthesis, which goes back to 2007,” said Egil Greve, Kappa CEO, in a press release. “Innovation and the value of our IP portfolio is a key driver of Kappa’s success, allowing us to serve our customers with the best performing and purest product possible. Protecting our intellectual property rights is very important to us and allows us to continue to invest in R&D and innovation.”

"Kappa will pursue an offensive enforcement strategy of our patents to protect our growing commercial product line and the associated manufacturing processes that we have invested significant resources into building up," added Greve.

This new patent expands on a previous patent from 2015 which protected the synthetic process of vitamin K2. By broadening protection to the intermediates within the vitamin K2 synthetic process, the patent also extends to finished products and import of products to the U.S. that include these intermediates via a synthesized ingredient.